

FIG. 1




FIG. 2




FIG. 3




FIG. 4





FIG. 5



\*  $p < 0.05$  VERSUS NO TREATMENT

FIG. 6

# Experimental Protocol

5TGM1




Figure 7

# Serum IgG<sub>2</sub> levels in 5TGM1-bearing mice




Figure 8



# Tumor Volume in Bone




Figure 9

# EFFECT OF PS/2 mAb TREATMENT ON SPLEEN WEIGHT




Figure 10

# EFFECT OF PS/2 TREATMENT ON SPLENOCYTES IN MICE WITH 5TGM1 MYELOMA





Figure 11

# EFFECT OF PS/2 mAb TREATMENT ON SPLENOCYTE FACS PROFILE

## DISEASE FREE




File: do111700.077  
Gate: G1  
Total Events: 10707

Acquisition Date: 17-Nov-00  
Gated Events: 9624  
Quad Location: 523, 25

| Quad | Events | % Gated | % Total | X Mean  | Y Mean  |
|------|--------|---------|---------|---------|---------|
| UL   | 9499   | 98.70   | 88.72   | 37.11   | 1120.67 |
| UR   | 3      | 0.03    | 0.03    | 5084.96 | 773.52  |
| LL   | 122    | 1.27    | 1.14    | 31.88   | 11.09   |
| LR   | 0      | 0.00    | 0.00    | ...     | ...     |

## UNTREATED




File: do111700.100  
Gate: G1  
Total Events: 11100

Acquisition Date: 17-Nov-00  
Gated Events: 9526  
Quad Location: 523, 25

| Quad | Events | % Gated | % Total | X Mean  | Y Mean  |
|------|--------|---------|---------|---------|---------|
| UL   | 4959   | 52.06   | 44.68   | 84.30   | 1023.41 |
| UR   | 1388   | 14.57   | 12.50   | 2377.81 | 704.20  |
| LL   | 2163   | 22.71   | 19.49   | 50.53   | 6.64    |
| LR   | 1016   | 10.67   | 9.15    | 3619.03 | 4.05    |

## PS/2 TREATED




File: do111700.120  
Gate: G1  
Total Events: 10934

Acquisition Date: 17-Nov-00  
Gated Events: 9561  
Quad Location: 523, 25

| Quad | Events | % Gated | % Total | X Mean  | Y Mean  |
|------|--------|---------|---------|---------|---------|
| UL   | 7868   | 82.29   | 71.96   | 58.00   | 1139.33 |
| UR   | 310    | 3.24    | 2.84    | 1922.82 | 897.47  |
| LL   | 1171   | 12.25   | 10.71   | 42.10   | 8.17    |
| LR   | 212    | 2.22    | 1.94    | 3153.17 | 3.62    |

## rat IgG2b TREATED



File: do111700.137  
Gate: G1  
Total Events: 10970

Acquisition Date: 17-Nov-00  
Gated Events: 9595  
Quad Location: 523, 25

| Quad | Events | % Gated | % Total | X Mean  | Y Mean |
|------|--------|---------|---------|---------|--------|
| UL   | 4910   | 51.17   | 44.76   | 84.95   | 975.19 |
| UR   | 1384   | 14.42   | 12.62   | 1937.36 | 694.49 |
| LL   | 1704   | 17.76   | 15.53   | 48.67   | 7.00   |
| LR   | 1597   | 16.64   | 14.56   | 3286.15 | 2.68   |

Figure 12

# EFFECT OF PS/2 mAb TREATMENT ON SPEEN TUMOR BURDEN




Figure 13

# EFFECT OF PS/2 mAB TREATMENT ON BONE MARROW CELLS IN MICE WITH 5TGM1 MYELOMA




Figure 14

EFFECT OF PS/2 TREATMENT ON BONE MARROW TUMOR BURDEN  
mIgG2b POSITIVE CELLS




Figure 15

# EFFECT OF PS/2 mAb TREATMENT ON 5TGM1 CELLS IN THE BLOOD




Figure 16



## EFFECT OF PS/2 TREATMENT ON BLOOD CHEMISTRY




Figure 17

EFFECT OF PS/2 mAb ON  
CIRCULATION mIgG2b LEVELS




Figure 18

C57/BI KaLwRaj MULTIPLE MYELOMA MODEL  
ACUTE TREATMENT PROTOCOLS




Figure 19

EFFECT OF PS/2 TREATMENT ON IgG2b POSITIVE CELLS  
ACUTE TREATMENT MODEL




Figure 20

# EFFECT OF ANTI VLA-4 ANTIBODY PS/2 ON TUMOR BURDEN IN SPLEEN




Figure 21

# EFFECT OF 6 DAYS OF PS/2 TREATMENT




Figure 22

# EFFECT OF 6 DAYS OF PS/2 TREATMENT ON BONE MARROW CELLS





Figure 23

# C57/BIKaLwRaj MODEL OF MULTIPLE MYELOMA COMBINATION TREATMENT WITH PS/2 AND MELPAHLAN



STGM1 CELLS (1E6) WERE INJECTED (I.V.) ON DAY 0  
EFFECTIVENESS OF TREATMENT WAS EVALUATED ON DAY 20 AND DAY 27

GROUPS N=3/GROUP

- DISEASE FREE CONTROL
- UNTREATED MYELOMA CONTROL
- MELPHALAN TREATMENT--100 MICROGRAMS/INJECTION
- PS/2 TREATMENT --100 MICROGRAMS/INJECTION
- MELPHALAN AND PS/2
- MELPAHLAN AND rIgG2b ISOTYPE CONTROL

Figure 24



# EFFECT OF TREATMENT ON mIgG2b PLASMA LEVELS




Figure 25

# EFFECT OF TREATMENT ON MYELOMA CELLS AT DAY 27




Figure 26

## EFFECT OF TREATMENT ON TUMOR BURDEN AT DAY 27





Figure 27

|                   | Day 20               | day 27             |
|-------------------|----------------------|--------------------|
|                   | PS/2 Plasma levels   | PS/2 Plasma levels |
| 8-PS/2            | none detected        | none detected      |
| 9-PS/2            | none detect d        | none detected      |
| 10-PS/2           | none detected        | none detected      |
| 11-melphalan+PS/2 | none detected        | none detected      |
| 12-melphalan+PS/2 | 3.7 $\mu\text{g/ml}$ | none detected      |
| 13-melphalan+PS/2 | none detected        | none detected      |

**Figure 28**

C57/BIKaLwRaj MODEL OF MULTIPLE MYELOMA  
 PS/2 AND ANTI VLA4 SMALL MOLECULE  
 LONG TERM TREATMENT



5TGM1 CELLS (1E6) INJECTED(I.V.) ON DAY 0  
 EFFECTIVNESS OF TREATMENT WAS EVALUATED ON DAY 20

- GROUPS N=2/GROUP
- DISEASE FREE CONTROL
  - UNTREATED MYELOMA CONTROL
  - PS/2 --100 micrograms/injection
  - Sm. Mol . 8809--3 mg/kg, 0.3 mg/kg or 0.03 mg/kg
  - Sm. Mol. 9257 CONTROL -- 3 mg/kg

Figure 29

# EFFECT OF LONG TERM TREATMENT ON MYELOMA CELLS




Figure 30

# EFFECT OF LONG TERM TREATMENT ON TUMOR BURDEN





Figure 31

C57/BIKaLwRaj MODEL OF MULTIPLE MYELOMA  
 PS/2 AND ANTI VLA4 SMALL MOLECULE  
 ACUTE TREATMENT



STGM1 CELLS (1E6) INJECTED(I.V.) ON DAY 0  
 PS/2 WAS GIVEN ON DAYS 15,16,17,18,19 AND 20  
 SMALL MOLECULE WAS GIVEN ON DAYS 15, 16 AND 17  
 EFFECTIVNESS OF TREATMENT WAS EVALUATED ON DAY 21

- GROUPS N=2/GROUP
- DISEASE FREE CONTROL
  - UNTREATED MYELOMA CONTROL
  - PS/2 --100 micrograms/injection
  - 8809--3 mg/kg, 0.3 mg/kg or 0.03 mg/kg
  - 9257 CONTROL -- 3 mg/kg

Figure 32



# EFFECT OF ACUTE TREATMENT ON MYELOMA CELLS




Figure 33

## EFFECT OF ACUTE TREATMENT ON TUMOR BUREN




Figure 34

# Experimental Protocol




Figure 35

# Inhibition of Hindleg Paralysis




Figure 36